|
Greetings,
The CDC has released the following updated guidance for the use of COVID-19 Vaccines. (As of Dec. 9, 2022)
- New recommendation for children ages 6 months–5 years who completed a Moderna primary series to receive 1 bivalent Moderna booster dose at least 2 months after completion of the primary series.
- The Moderna COVID-19 Vaccine, Bivalent is also authorized for use in individuals 6 years and older as a single booster dose at least two months after completion of either primary vaccination with any authorized or approved COVID-19 vaccine, or receipt of the most recent booster dose with any authorized or approved monovalent COVID-19 vaccine.
- The Pfizer-BioNTech COVID-19 Vaccine, Bivalent is authorized for administration in individuals 5 years of age and older as a single booster dose at least two months after completion of either primary vaccination with any authorized or approved COVID-19 vaccine, or receipt of the most recent booster dose with any authorized or approved monovalent COVID-19 vaccine.
- The previously authorized 3-dose Pfizer-BioNTech primary series for children ages 6 months–4 years has been revised as follows:
- A monovalent Pfizer-BioNTech vaccine is administered for the first and second doses, followed by 1 bivalent Pfizer-BioNTech vaccine as the third primary series dose, at least 2 months after the second monovalent primary series dose.
- A booster dose is not authorized for children in this age group that have already completed the original (monovalent) Pfizer-BioNTech 3-dose primary vaccine series.
To view all updates, please visit CDC’s Interim Clinical Considerations for Use of COVID-19 Vaccines Currently Approved or Authorized in the United States
If you have any question, please reach out to Immunize@health.ok.gov.
Thank you,
Immunization Service | Oklahoma State Department of Health |
